• Rare and Orphan Disease Focused
  • Experienced Management Team
  • Rare Pediatric Designation opportunity for lead products
  • Targeting Approval for lead asset in 2024.
  • Internal commercial infrastructure planned for US and EU markets. Marketing partnerships established spanning 60 countries
  • Strong KOL support

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a clinical stage specialty pharmaceutical company focused on the development and commercialization of therapeutic drug products that treat rare and orphan diseases. Our mission is very simple; to bring hope where there is currently none. We are totally committed to addressing critical, unmet medical needs for patients, their families, communities and care teams.

Quoin’s innovative pipeline comprises four products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, Scleroderma and others. The company plans to establish a sales infrastructure to commercialize its products in both US and Europe and has entered into eight separate strategic licensing partnerships spanning 60 countries including Canada, Australia, New Zealand, the Middle East, China, Hong Kong, Taiwan, Central and Eastern Europe, the Baltic States and several countries in Latin America.

We are dedicated to finding unique solutions for rare and orphan indications and will continue to expand our pipeline of products to address the unmet needs of underserved and neglected patient populations.

Our History

Our Team

Executive Officers

Dr. Michael Myers
Dr. Michael Myers
Co-Founder, Chairman, Chief Executive Officer and Director
Denise Carter
Denise Carter
Co-Founder, Chief Operating Officer and Director
Gordon Dunn
Gordon Dunn
Chief Financial Officer

Board of Directors

Dennis H. Langer, MD, JD
Dennis H. Langer, MD, JD
Director
Natalie Leong
Natalie Leong
Director
James Culverwell
James Culverwell
Director
Joseph Cooper
Joseph Cooper
Director
Michael Sember
Michael Sember
Director

Scientific Advisors

Dr. Amy Paller
Professor Alan Irvine

Our Partners

Quoin Pharmeceuticals Partners

A Message from the CEO

At Quoin, we understand that rare diseases are only rare if you don’t live with one.

While researchers have made significant progress in diagnosing, treating and even preventing many rare diseases, the vast majority still lack effective therapeutic drug products.

Our mission could not be clearer; we want to bring hope where there is currently none. We are targeting neglected and underserved patient populations who face a daily reality of limited or no treatment options.

We strive every day to advance our product pipeline, our distribution channels and our commercialization capabilities to ensure we are positioned to reach every single patient who could benefit from our products.

To the neglected rare disease community, we have a very simple message. We will not stop our efforts until we succeed.

All the best,
Dr. Michael Myers, CEO